-
1958
DEVA "Doktor, Eczacı ve Alatları" (Physicians, Pharmacists and Diagnostics) Sanayi ve Ticaret A.Ş. was incorporated.
-
1960
The first manufacturing facility is established in Tünel, Beyoğlu
-
1963
Bomonti pharmaceutical plant was opened.
-
1968
The ampoule plant was set up.
-
1970
The production of Tetracycline and Oxytetracycline was realized as the first pharmaceutical raw material in Turkey.
-
1973
- Vetaş Veteriner ve Tarım İlaçları A.Ş. is established to manufacture and market veterinary and agricultural products in 1973 under the umbrella of the company, Deva Holding.
- The first products placed on the market were Vetimisin Powder for Solution for Injection and Vitaform Powder for Oral Solution. Vetimisin remains the market leader since the first day it was placed on the market.
- The largest pharmaceutical manufacturing facility was purchased from Farmitalia.
-
1976
Vetaş Oksitosin , the first oxytocin for veterinary use, and Vetaş Atropin , the first anticholinergic product in the Turkish market, are launched
-
1978
Carlo Erba pharmaceutical plant was purchased.
-
1981
With the production of Gentamicine in its active pharmaceutical ingredient manufacturing facilities, it was listed among 5 establishments to produce this active ingredient throughout the world.
-
1986
- Nervit Kompoze , the first B1, B6 vitamin for veterinary use, product in the Turkish market, are launched.
- The shares of DEVA Holding started to be traded on the Istanbul Stock Exchange.
-
1987
The first Gentamycin-containing products are launched in the market: Gentavet Solution for Injection, Gentavet-G Eye and Ear Drops, and Gentavet-D Skin ointment.
-
2006
The majority ownership of DEVA Holding was transferred to EastPharma Limited, a business venture of GEM Global Equities Management S.A. In connection with this restructuring, Phillip Haas was elected as the new Chairman of the Board of Directors in July 2006.
-
2007
The company headquarters moved to its new building in Halkalı. Production plant construction was started in çerkezköy and Köseköy İzmit.
-
2009
R&D center “DEVARGE” was established. SAP (Systems, Applications and Products in Data Processing), the world’s best and most effective reporting system for manufacturing sales and supply channels, is successfully introduced.
-
2013
DEVA was deemed worthy of the first prize in the “R&D Study of the Year” branch of the Golden Mortar competition.
-
2014
- DEVA Holding facilities, toll manufacturing products for Vetaş, receives GMP certification by Turkish Ministry of Food, Agriculture and Animal Husbandry.
- Vetaş introduces the pre-dispensed Beta-lactam group of products.
- Aquaculture products (Diaqua, Geosol fish, Seaflor) were introduced as a new product segment.
- Launched Vetakademi Kampüs, with the slogan “Led by Science,” with educational meetings to respond to scientific needs of veterinarians.
-
2015
- DEVA was selected as the Best R&D Company by the Turkish Ministry of Science, Technology and Industry.
- DEVA, was selected as the Best R&D Company by Eczacı Magazine. Vetamoks LA Suspension for Injection, an antibacterial containing amoxicillin and Setrim Powder for Oral Solution, containing erythromycin, is lunched
-
2016
As of 30.12.2016, it has merged with DEVA Holding A.Ş., the main shareholder in the company. It will continue operating within DEVA Holding A.Ş. with the Vetaş brand. Kartepe Manufacturing Plant received FDA approval.
-
2018
- 4 new products (Dectocide Solution for Injection, Spectovet Oral Gel, Betacolin Suspension for Injection and Ricogard Solution for Injection) were launched.
- Turkey’s largest pharmaceutical logistics center, started its operations with 32000 pallet capacity.
-
2019
- Vetimisin RTU Suspension for Injection and Paromisin Powder for Oral Solution were introduced.
-
2020
- 6 new products were launched.
- Touxflor 300 Solution for Injection
- Vetalben %10 Oral Suspension
- Klavetsilin RTU Suspension for Injection
- Histavet-C Solution for Injection
- Multidry DC,
- Vetkalfos-R Solution for Injection
- 6 new products were launched.
-
2021
- The first sustainability report has been published
- 6 new products were launched.
- Touxflor 450 Solution for Injection
- Vermifen Oral Suspension
- Tulabiotic Solution for Injection
-
2022
- US FDA-ABD and GMP renewal approvals were received at Çerkezköy-I ve Çerkezköy-II Manufacturing Facilities.
- GMP renewal approvals were received at Kartepe Manufacturing Facilities.
- Altın Havan ve 11.Kimya Ar-Ge Proje Pazarı ödülleri alınmıştır.
- Golden Mortar Award and 11th Chemistry R&D Project Market Award was granted
- 2 new products were launched.
- Hepankton Solution for Injection
- Bromoscol Solution for Injection
